CA panel deems Sovaldi a "low value" treatment

|By:, SA News Editor

California Technology Assessment Forum members give a "low value" rating to Gilead's (GILD) pricey hepatitis C treatment Sovaldi citing its high cost. The vote is non-binding but could influence coverage decisions by payers.

The panel agrees that not all hep C patients require the most expensive drugs. If California treated every patient with liver damage it would cost the state over $6B.

Sovaldi's treatment regimen costs $84,000 compared to $66,000 for J&J's (JNJ) Olysio.